[6-K] BioHarvest Sciences Inc. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Eos Energy Enterprises, Inc. (EOSE) has filed a Form 144, indicating the intent of an insider to sell restricted shares under Rule 144.

• Shares to be sold: 24,124 common shares
• Estimated market value: US $125,565.42
• Broker: UBS Financial Services Inc., New York
• Planned sale date: 07 July 2025
• Total shares outstanding: 227,589,833
• Source of shares: RSU vesting on 03 July 2025
• Prior insider activity: The same account holder sold 152,856 shares on 16 May 2025 for US $1,048,853

The proposed sale represents roughly 0.01 % of EOSE’s outstanding shares. Rule 144 filings are routine for executives monetising equity compensation and do not, by themselves, signal a change in company fundamentals. However, the filing does extend a recent pattern of insider sales that investors may wish to monitor.

Positive

• Sale size is immaterial—about 0.01 % of shares outstanding, limiting market impact
• Shares originate from RSU vesting, indicating routine monetisation of compensation rather than strategic divestment

Negative

• Continued insider selling trend (over 177 k shares disclosed in two filings within three months) may pressure investor sentiment

Insights

Financial Analyst

TL;DR Small Form 144 sale (24 k shares) follows larger May sale; immaterial to float but continues insider selling trend.

The 24,124-share sale equates to roughly US $125 k and less than 0.01 % of the 227.6 million shares outstanding, implying negligible dilution or market impact. The shares stem from a recent RSU vesting, a common liquidity event. Still, coupled with May’s 152,856-share sale (US $1.05 m), it reflects continued insider disposition. While the dollar amounts are modest relative to EOSE’s market cap, repeated insider sales can weigh on sentiment in a stock already sensitive to funding and execution risks. Overall impact: neutral to slightly negative for sentiment, immaterial for valuation.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission file number: 001-42389

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SUBMITTED HEREWITH

Exhibits:

Exhibit	Description
99.1	Material Change Report dated July 4, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOHARVEST SCIENCES INC.
	(Registrant)
Date: July 7, 2025	/s/ David Ryan
	Name: David Ryan
	Title: Vice-President, Investor Relations & Secretary

FAQ

How many EOSE shares are proposed for sale under this Form 144?

24,124 common shares are scheduled for sale.

What is the estimated market value of the planned EOSE share sale?

The filing lists an aggregate market value of US $125,565.42.

When will the EOSE insider sell the shares?

The approximate sale date is 07 July 2025.

What percentage of EOSE’s outstanding shares does this sale represent?

Roughly 0.01 % of the 227,589,833 shares outstanding.

Were there recent insider sales at EOSE prior to this filing?

Yes. 152,856 shares were sold on 16 May 2025 for US $1,048,853.